CJ-15314 is under clinical development by HK inno.N and currently in Phase I for Rheumatoid Arthritis. According to GlobalData, Phase I drugs for Rheumatoid Arthritis have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CJ-15314’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CJ-15314 overview
CJ-15314 is under development for the treatment of rheumatoid arthritis, psoriasis and atopic dermatitis. The drug candidate is administered orally as capsule and topically as ointment. The drug candidate is a new chemical entity and acts by targeting Janus kinase, which is non-receptor tyrosine kinases.
HK inno.N overview
HK inno.N, a subsidiary of Kolmar Korea Co Ltd, is a manufacturer of active pharmaceutical ingredients and prescription drugs. The company’s products include prescription drugs, healthcare daily products and beauty products. Prescription products include OMAP plus wonju, omaf plus one ferry, dafaen tablet. Healthcare daily products include condition stick, red ginseng jin jeong seong, refresh plain. Beauty products include scalpmed gold biome repair shampoo, scalpmed gold biome repair treatment, phyto collagen eye serum patch, among others. It markets its products under the brand names including Scalpmed and Condition. HK inno.N is headquartered in Seoul, South Korea.
For a complete picture of CJ-15314’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
